Tiverton Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Tiverton Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$96K	Hold	588	–	–	﹤0.01%	647
2019 Q2	$139K	Hold	588	–	–	0.01%	591
2019 Q1	$155K	Hold	588	–	–	0.01%	543
2018 Q4	$54K	Buy	588 +9	+2%	+$1.23K	﹤0.01%	442
2018 Q3	$111K	Hold	579	–	–	0.01%	362
2018 Q2	$125K	Buy	+579	New	+$131K	0.01%	357

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Tiverton Asset Management's DNTH Position: Q3 2019 in Review

Tiverton Asset Management held its Dianthus Therapeutics (DNTH) position steady in Q3 2019 at 588 shares worth $96K. The position accounts for ﹤0.01% of the portfolio, ranked #647.

Tiverton Asset Management first reported a position in DNTH in Q2 2018 and has held it in 6 quarters since. The position peaked at $155K in Q1 2019. 72 funds tracked by Wall St. Rank hold DNTH as of Q3 2019.

Tiverton Asset Management held 588 shares of Dianthus Therapeutics worth $96K as of Q3 2019.
Tiverton Asset Management left its Dianthus Therapeutics share count unchanged in Q3 2019.
Dianthus Therapeutics made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #647 holding.
Tiverton Asset Management first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 6 quarters since.
Tiverton Asset Management's Dianthus Therapeutics position peaked at $155K in Q1 2019.
72 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.